What is Aflibercept-Mrbb used for?

Aflibercept-Mrbb (brand name Ahzantive) is a Anti-VEGF (Ophthalmology) indicated for See full prescribing information.

How does Aflibercept-Mrbb work?

Aflibercept-Mrbb works through the following mechanism: Other agent.

What are the most common side effects of Aflibercept-Mrbb?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for Aflibercept-Mrbb. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is Aflibercept-Mrbb the same as Ahzantive?

Ahzantive is a brand name for Aflibercept-Mrbb. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

Aflibercept-Mrbb

Anti-VEGF (Ophthalmology)

Brand names: Ahzantive

Intravitreal

Mechanism of Action

Other agent

Indications

See full prescribing information

Contraindications

• pruritus
• urticaria
• severe anaphylactic/anaphylactoid reactions
• or severe intraocular inflammation. Ocular or periocular infections (4.1) Active intraocular inflammation (4.2) Hypersensitivity (4.3)

FDA Warnings

WARNINGS AND PRECAUTIONS 5
3 Thromboembolic Events There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products
ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)
2) There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors

Known Side Effects

0 documented side effects by frequency

No structured side effect data available.

Community Discussions

No community discussions found for Aflibercept-Mrbb yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → Aflibercept-Mrbb openFDA label JSON → Aflibercept-Mrbb FAERS adverse-event reports → Aflibercept-Mrbb ClinicalTrials.gov → completed Phase 2+ trials of Aflibercept-Mrbb

Compare With

4 available comparisons

Formulations

Dosage Forms

Tablet

Route

Intravitreal